Sunitinib Treatment Of Renal Adjuvant Cancer (S-trac): A Randomized Double-blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent Rcc
Sunitinib Treatment Of Renal Adjuvant Cancer (S-trac): A Randomized Double-blind Phase 3 Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent Rcc
To compare the disease free survival time and safety of sunitinib with placebo in adjuvant treatment patients at high risk of recurrent kidney cancer after surgery.
Inclusion Criteria:
Exclusion Criteria:
Los Angeles, California 90095, United States
Chapel Hill, North Carolina 27599-7600, United States
East Bentleigh, Victoria 3165, Australia
Suzhou, Jiangsu 215006, China
Shanghai, Shanghai Municipality 200032, China
Shanghai, Shanghai Municipality 200127, China
Hangzhou, Zhejiang 310009, China
Chongqing, 400038, China
Bogota, Cundinamarca 0, Colombia
Ústí nad Labem, 401 13, Czechia
Homburg/Saar, 66421, Germany
Jena, 07740, Germany
München, 81377, Germany
Athens, 11528, Greece
Genova, 16132, Italy
Lodz, 90-549, Poland
Lodz, 90-549, Poland
Poznan, 60-569, Poland
Seongnam-si, Gyeonggi-do 13620, South Korea